These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31615365)

  • 21. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    Lee TH; Chan A; Bryan W; Park L; Hashem M; Townsend M; Moylan C; Britt R; Choi S; Naggie S
    J Viral Hepat; 2021 Apr; 28(4):630-636. PubMed ID: 33378562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
    Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
    J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HCV eradication in veterans with underlying mental health disorders and substance use.
    Ifeachor AP; Houck KK; Schulte S; Ansara E; Johnson AJ; Carr TA; Liangpunsakul S
    J Am Pharm Assoc (2003); 2020; 60(6):1037-1043.e3. PubMed ID: 32948462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
    Belperio PS; Shahoumian TA; Loomis TP; Backus LI
    J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing access for veterans with hepatitis C by enhancing use of clinical pharmacy specialists.
    Ourth HL; Groppi JA; Morreale AP; Jorgenson T; Himsel AS; Jacob DA
    J Am Pharm Assoc (2003); 2019; 59(3):398-402. PubMed ID: 30853345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
    Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
    Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychiatric services and prescription fills among veterans with serious mental illness in methadone maintenance treatment.
    Marienfeld C; Rosenheck RA
    J Dual Diagn; 2015; 11(2):128-35. PubMed ID: 25781867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012-2019.
    Hawks L; Wang EA; Butt AA; Crystal S; Keith McInnes D; Re VL; Cartwright EJ; Puglisi LB; Haque LYK; Lim JK; Justice AC; McGinnis KA
    Am J Public Health; 2023 Feb; 113(2):162-165. PubMed ID: 36480765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose control and medication adherence among veterans with diabetes and serious mental illness: does collocation of primary care and mental health care matter?
    Long JA; Wang A; Medvedeva EL; Eisen SV; Gordon AJ; Kreyenbuhl J; Marcus SC
    Diabetes Care; 2014 Aug; 37(8):2261-7. PubMed ID: 24879839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
    Isakov V; Chulanov V; Abdurakhmanov D; Burnevich E; Nurmukhametova E; Kozhevnikova G; Gankina N; Zhuravel S; Romanova S; Hyland RH; Lu S; Svarovskaia ES; McNally J; Brainard DM; Ivashkin V; Morozov V; Bakulin I; Lagging M; Zhdanov K; Weiland O
    Infect Dis (Lond); 2019 Feb; 51(2):131-139. PubMed ID: 30499360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
    Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
    J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
    Zalawadiya SK; Lindenfeld J; Shah A; Wigger M; Danter M; Brinkley DM; Menachem J; Punnoose L; Balsara K; Brown Sacks S; Ooi H; Perri R; Awad J; Smith S; Fowler R; O'Dell H; Darragh C; Ruzevich-Scholl S; Schlendorf K
    ASAIO J; 2020 May; 66(5):553-558. PubMed ID: 31425256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.